Key facts
- Cystotech’s last known valuation is $11.1M (May 2025).
- It has raised $5.5M; the latest was Later Stage VC ($1.9M) in Jan 2026.
- Notable investors include InnoFounder, Denmark's Export and Investment Fund, CancerX (USA), Aarhus University, Danish Business Angels — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Cystotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Cystotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cystotech
Developer of an artificial intelligence-based support technology designed to transform the future of bladder cancer treatment. The company's technology focuses is on changing clinical practice, favoring patient outcomes and driving healthcare toward improved personalised treatment, enabling healthcare professionals and organizations to focus on diagnostic performance and the use of less invasive approaches to treatment for the benefit of patients and healthcare costs.
- Sector
- Healthcare
- HQ
- Aarhus Centrum, Denmark
- Founded
- 2021
- Employees
- 20
- Website
- cystotech.com/
- Ownership
- Privately Held (backing)
Cystotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cystotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cystotech in its N-PORT filings yet. We sweep new filings monthly.